Harmon Stein, MD
Ophthalmology · Levittown, PANPI 1588624357
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 197 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by Alcon at 42.6% of the total.
Across 197 payments — averaging $33.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$3K
- AbbVie$662
- Johnson & Johnson Surgical Vision, Inc.$549
- NEW World Medical,inc.$374
- Galderma Laboratories, L.p.$296
- Amgen$279
- plus $2K from 26 others
What the payments were for
- Food & beverage$6,52699%
- Education$70%
- Gifts$641%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 81 | $2,809 |
| AbbVie(2 entities) | 19 | $662 |
| Johnson & Johnson Surgical Vision, Inc. | 7 | $549 |
| NEW World Medical,inc. | 10 | $374 |
| Galderma Laboratories, L.p. | 13 | $296 |
| Amgen(2 entities) | 10 | $279 |
| Bausch & Lomb Americas Inc. | 11 | $213 |
| Mallinckrodt Hospital Products Inc. | 2 | $153 |
| Glaukos Corporation | 2 | $142 |
| Rxsight Inc | 1 | $135 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $121 |
| Aerie Pharmaceuticals, Inc. | 1 | $121 |
| Sight Sciences, Inc. | 1 | $114 |
| Harrow Eye, LLC | 5 | $96 |
| Kala Pharmaceuticals, Inc. | 3 | $67 |
| Sun Pharmaceutical Industries Inc. | 4 | $54 |
| Merz North America, Inc. | 1 | $50 |
| Rayner Intraocular Lenses Limited | 2 | $44 |
| Ocular Therapeutix, Inc. | 2 | $43 |
| Tarsus Pharmaceuticals, Inc. | 1 | $38 |
| Oyster Point Pharma, Inc. | 2 | $32 |
| Revance Therapeutics, Inc. | 1 | $28 |
| LKC Technologies, Inc. | 2 | $25 |
| Carl Zeiss Meditec USA, Inc. | 1 | $22 |
| ABB Con-cise Optical Group LLC | 1 | $22 |
| Tearlab Corp | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Spark Therapeutics, Inc. | 1 | $19 |
| Travere Therapeutics, Inc. | 1 | $16 |
| Novartis | 1 | $14 |
| Eyevance Pharmaceuticals LLC | 1 | $12 |
| Oasis Medical, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wavelight Refractive Suite$214
- Hydrus Microstent$167
- Kahook Dual Blade$161
- Streamline Surgical System$161
- Ahmed Glaucoma Valve$161
- RXSIGHT CONTACT LENS$135
- RXSIGHT INJECTOR CARTRIDGE$135
- RXSIGHT INJECTOR HANDPIECE$135
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$135
- LIGHT ADJUSTABLE LENS (LAL)$135
- DYSPORT$133
- Clareon$131
- AcrySof IQ PanOptix$130
- LUMIGAN$125
- COMBIGAN$125
- TEPEZZA$125
- ACTHAR$124
- Tecnis Multifocal Family of 1-piece IOLS$123
- Rhopressa$121
- Rocklatan$121
How this compares
$6,597 in reported general payments places this provider in the 85th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 120 | $58,996 |
| Prednisolone Acetate | 665 | $21,267 |
| RocklatanNetarsudil Mesylat/Latanoprost | 39 | $21,223 |
| RestasisCyclosporine | 13 | $16,138 |
| Brimonidine Tartrate | 61 | $11,131 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 59 | $9,860 |
| Ketorolac Tromethamine | 550 | $6,566 |
| CombiganBrimonidine Tartrate/Timolol | 18 | $5,911 |
| Travoprost | 26 | $5,661 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 14 | $4,425 |
| Ofloxacin | 417 | $4,018 |
| Latanoprost | 185 | $2,401 |
| ErythromycinErythromycin Base | 145 | $1,808 |
| Timolol Maleate | 26 | $1,701 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 94 | $1,367 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $662 | $81,045151 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $121 | $21,22339 claims |
| AlconSimbrinza | $2,809 | $4,42514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 920 ophthalmology providers in Pennsylvania.
Other ophthalmology in Levittown
- Julia HallerPhiladelphia$1.5M
- Francis MahPittsburgh$1.1M
- Brandon AyresBala Cynwyd$929K
- David AlmeidaErie$734K
- Carl RegilloPlymouth Meeting$721K
- Robert NoeckerPittsburgh$632K
- Beeran MeghparaPhiladelphia$496K
- Michael KlufasPlymouth Meeting$393K
- Jonathan MyersPhiladelphia$359K
- Mark BlecherPhiladelphia$357K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.